Escalon Medical Corp.
Escalon Medical Corp. (ESMC) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Escalon Medical Corp. (ESMC), featuring income statements, balance sheets, and cash flow data.
Escalon Medical Corp. (ESMC) Income Statement & Financial Overview
Explore comprehensive income reports for Escalon Medical Corp. ESMC, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $3.22M | $2.78M | $3.47M | $2.70M |
| Cost of Revenue | $1.65M | $1.57M | $2.00M | $1.58M |
| Gross Profit | $1.57M | $1.21M | $1.47M | $1.12M |
| Gross Profit Ratio | $0.49 | $0.44 | $0.42 | $0.41 |
| R&D Expenses | $155940.00 | $140859.00 | $172976.00 | $155848.00 |
| SG&A Expenses | $1.16M | $1.10M | $1.16M | $1.12M |
| Operating Expenses | $1.32M | $1.24M | $1.33M | $1.27M |
| Total Costs & Expenses | $2.96M | $2.81M | $3.33M | $2.85M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $4883.00 | $5262.00 | $3897.00 | $5541.00 |
| Depreciation & Amortization | $9852.00 | $10627.00 | $19252.00 | $3583.00 |
| EBITDA | $260756.00 | -$16328.00 | $157555.00 | -$153025.00 |
| EBITDA Ratio | $0.08 | -$0.006 | $0.05 | -$0.06 |
| Operating Income | $255904.00 | -$26955.00 | $138303.00 | -$156610.00 |
| Operating Income Ratio | $0.08 | -$0.010 | $0.04 | -$0.06 |
| Other Income/Expenses (Net) | $245.77M | -$5262.00 | -$3897.00 | -$5541.00 |
| Income Before Tax | $246.02M | -$32217.00 | $134406.00 | -$162149.00 |
| Income Before Tax Ratio | $76.39 | -$0.01 | $0.04 | -$0.06 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$3.00 |
| Net Income | $246021.00 | -$32217.00 | $134406.00 | -$162149.00 |
| Net Income Ratio | $0.08 | -$0.01 | $0.04 | -$0.06 |
| EPS | $33.18 | -$0.004 | $0.02 | -$0.02 |
| Diluted EPS | $17.47 | -$0.004 | $0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $7.42M | $7.42M | $7.42M | $7.42M |
| Weighted Avg Shares Outstanding (Diluted) | $14.08M | $7.42M | $7.42M | $7.42M |
The company's financials show resilient growth, with revenue advancing from $2.70M in Q3 2024 to $3.22M in Q2 2025. Gross profit remained healthy with margins at 49% in Q2 2025 compared to 41% in Q3 2024. Operating income hit $255904.00 last quarter, sustaining a consistent 8% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $260756.00. Net income rose to $246021.00, while earnings per share reached $33.18. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan